TMDX TransMedics Group Inc
Price (delayed)
$63.03
Market cap
$2.12B
P/E Ratio
58.91
Dividend/share
N/A
EPS
$1.07
Enterprise value
$2.3B
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need
Highlights
The revenue has soared by 83% YoY and by 10% from the previous quarter
TMDX's gross profit has surged by 70% year-on-year and by 10% since the previous quarter
The quick ratio has contracted by 13% YoY but it has grown by 3.6% from the previous quarter
The gross margin has contracted by 7% YoY
Key stats
What are the main financial stats of TMDX
Market
Valuations
Earnings
Shares outstanding
33.66M
Market cap
$2.12B
Enterprise value
$2.3B
Price to earnings (P/E)
58.91
Price to book (P/B)
9.25
Price to sales (P/S)
4.74
EV/EBIT
45.88
EV/EBITDA
32.2
EV/Sales
5.22
Revenue
$441.54M
Gross profit
$262.08M
Operating income
$37.5M
Net income
$35.46M
EBIT
$50.19M
EBITDA
$71.51M
Free cash flow
-$80.94M
Per share
Balance sheet
Liquidity
EPS
$1.07
EPS diluted
$1.01
Free cash flow per share
-$2.44
Book value per share
$6.81
Revenue per share
$13.29
TBVPS
$23.79
Total assets
$804.08M
Total liabilities
$575.47M
Debt
$518.29M
Equity
$228.6M
Working capital
$437.3M
Debt to equity
2.27
Current ratio
8.3
Quick ratio
7.26
Net debt/EBITDA
2.53
Margins
Efficiency
Dividend
EBITDA margin
16.2%
Gross margin
59.4%
Net margin
8%
Operating margin
8.5%
Return on assets
4.6%
Return on equity
18%
Return on invested capital
5.8%
Return on capital employed
6.7%
Return on sales
11.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TMDX stock price
How has the TransMedics Group stock price performed over time
Intraday
-6.04%
1 week
-3.46%
1 month
-11.5%
1 year
-23.47%
YTD
1.09%
QTD
1.09%
Financial performance
How have TransMedics Group's revenue and profit performed over time
Revenue
$441.54M
Gross profit
$262.08M
Operating income
$37.5M
Net income
$35.46M
Gross margin
59.4%
Net margin
8%
The company's net margin has surged by 177% YoY
The operating margin has surged by 171% year-on-year and by 9% since the previous quarter
The revenue has soared by 83% YoY and by 10% from the previous quarter
TMDX's gross profit has surged by 70% year-on-year and by 10% since the previous quarter
Growth
What is TransMedics Group's growth rate over time
Valuation
What is TransMedics Group stock price valuation
P/E
58.91
P/B
9.25
P/S
4.74
EV/EBIT
45.88
EV/EBITDA
32.2
EV/Sales
5.22
TransMedics Group's EPS has increased by 8% QoQ
TMDX's equity has surged by 67% year-on-year and by 9% since the previous quarter
The stock's P/B is 48% less than its last 4 quarters average of 18.9 and 20% less than its 5-year quarterly average of 12.3
The revenue has soared by 83% YoY and by 10% from the previous quarter
The P/S is 72% lower than the 5-year quarterly average of 18.0 and 50% lower than the last 4 quarters average of 10.0
Efficiency
How efficient is TransMedics Group business performance
The ROA is up by 4.5% since the previous quarter
TransMedics Group's return on equity has decreased by 3.7% QoQ
TransMedics Group's return on sales has decreased by 2.6% QoQ
Dividends
What is TMDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TMDX.
Financial health
How did TransMedics Group financials performed over time
The total assets is 40% more than the total liabilities
The total assets has grown by 14% YoY and by 2.4% from the previous quarter
The quick ratio has contracted by 13% YoY but it has grown by 3.6% from the previous quarter
The company's debt is 127% higher than its equity
TMDX's equity has surged by 67% year-on-year and by 9% since the previous quarter
TMDX's debt to equity is down by 40% year-on-year and by 8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.